Thrombospondin-1 polypeptides and methods of using same
The invention features thrombospondin-1 (TSP-1) polypeptides (e.g., 3TSR-Fc fusion proteins), nucleic acid molecules encoding the TSP-1 polypeptides, and compositions thereof. The invention also features methods of making and using the TSP-1 polypeptides of the invention (e.g., using 3TSR-Fc fusion proteins to treat a subject having a disorder associated with pathological angiogenesis, e.g., cancer, e.g., epithelial ovarian cancer (EOC)).
1. A method of treating a subject having an ovarian cancer, the method comprising administering to the subject a polypeptide comprising a thrombospondin-1 (TSP-1) domain, wherein the TSP-1 domain comprises a 3 TSP-1 repeat (3TSR) domain, at a dosage of about 0.01 mg/kg/wk to about 3.5 mg/kg/wk, thereby reducing the presence of metastatic peritoneal tumors and ascites in the subject.
2. The method of claim 1 , wherein the dosage is about 0.01 mg/kg/wk to about 1 mg/kg/wk.
3. The method of claim 2 , wherein the reduction in the presence of metastatic peritoneal tumors and ascites in the subject is a reduction of 75% or more in the volume of metastatic peritoneal tumors and ascites compared to prior to administration of the polypeptide.
4. The method of claim 3 , wherein the reduction in the presence of metastatic peritoneal tumors and ascites in the subject is a reduction of 99% or more in the volume of metastatic peritoneal tumors and ascites compared to prior to administration of the polypeptide.
5. The method of claim 1 , wherein the polypeptide is administered to the subject immediately after diagnosis of the ovarian cancer or clinical recognition of metastatic peritoneal tumors and ascites.
6. The method of claim 1 , wherein at least one dose of the polypeptide is administered to the subject.
7. The method of claim 1 , wherein the ovarian cancer is an epithelial ovarian cancer (EOC).
8. The method of claim 7 , wherein the EOC is a Stage III EOC.
9. The method of claim 7 , wherein the EOC is a Stage IV EOC.
10. The method of claim 1 , wherein the 3TSR domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 7.
11. The method of claim 1 , wherein the polypeptide is administered intravenously, subcutaneously, intramuscularly, intradermally, percutaneously, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostatically, intrapleurally, intratracheally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, peritoneally, subconjunctivally, intravesicularlly, mucosally, intrapericardially, intraumbilically, intraocularly, orally, topically, locally, by inhalation, by injection, by infusion, by continuous infusion, by localized perfusion bathing target cells directly, by catheter, by lavage, in cremes, or in lipid compositions.
12. The method of claim 2 , wherein the dosage is about 0.01 mg/kg/wk to about 0.1 mg/kg/wk.
13. The method of claim 1 , wherein the polypeptide further comprises a fragment crystallizable (Fc) region.
14. The method of claim 13 , wherein the Fc region comprises a CH2 domain and a CH3 domain.
15. The method of claim 14 , wherein the CH2 domain and the CH3 domain are heavy chain constant domains of an immunoglobulin selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.
16. The method of claim 13 , wherein the TSP-1 domain and the Fc region are positioned relative to each other in an N-terminal to C-terminal direction as follows: X-TSP-1 domain-Y-Fc region-Z,
wherein each of X, Y, and Z is absent or is an amino acid sequence of at least one amino acid.
17. The method of claim 13 , wherein the TSP-1 domain and the Fc region are positioned relative to each other in an N-terminal to C-terminal direction as follows: X-Fc region-Y-TSP-1 domain-Z,
wherein each of X, Y, and Z is absent or is an amino acid sequence of at least one amino acid.
18. The method of claim 13 , wherein the Fc region is conjugated to a functional moiety.
19. The method of claim 18 , wherein the functional moiety is a dye, a chemotherapeutic agent, a drug, a growth inhibitory agent, a toxin, or a radioactive isotope.
20. The method of claim 10 , wherein the 3TSR domain comprises the amino acid sequence of SEQ ID NO: 7.
21. The method of claim 1 , wherein the reduction in the presence of metastatic peritoneal tumors and ascites in the subject is a reduction of 75% or more in the volume of metastatic peritoneal tumors and ascites compared to prior to administration of the polypeptide.
22. The method of claim 1 , wherein the polypeptide is administered once per week.
23. The method of claim 1 , wherein the polypeptide is administered twice per week.
24. The method of claim 1 , wherein the polypeptide is administered continuously.